Actos® MDL Lawsuit Update by Schlichter, Bogard & Denton, LLP: First Actos® Trial in Federal Court Begins on January 27, 2014

Schlichter, Bogard & Denton, LLP is investigating and pursuing claims on behalf of individuals who allege that they have been diagnosed with bladder cancer after taking the diabetes medication Actos® for more than one year.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

Kristine Kraft of Schlichter, Bogard & Denton, LLP

We are vigorously pursuing claims on behalf of individuals who allege that they or their loved ones have been diagnosed with bladder cancer as a result of taking Actos for more than one year.

St. Louis, MO (PRWEB) January 29, 2014

The first trial in the Multidistrict Litigation In re: Actos® (Pioglitazone) Products Liability Litigation, MDL 2299, begins on Monday, January 27, 2014 with opening statements expected to occur on February 3, 2014. The Actos® Multidistrict Litigation (MDL 2299) is currently pending in the United States District Court for the Western District of Louisiana before The Honorable Judge Rebecca F. Doherty. According to the most recent report issued by the Judicial Panel on Multidistrict Litigation, there are nearly 2,700 cases currently on file against Takeda Pharmaceuticals, the manufacturer of the diabetes drug Actos®, in MDL 2299.

In addition to the Multidistrict Litigation (MDL 2299) pending in federal court, there is also a consolidated state court litigation pending in Cook County Circuit Court in Chicago, Illinois. There are approximately 3,000 Actos® bladder cancer cases currently on file against Takeda Pharmaceuticals in Cook County before The Honorable Judge Deborah Mary Dooling (In re Actos® Litigation, Case No. 2011 L 10011). The first trial in the Cook County Actos® litigation is scheduled to begin in March 2014.

Actos® is a medication prescribed to control glucose (blood sugar) in adults with Type 2 diabetes. The Food and Drug Administration (“FDA”) approved Actos® in 1999. The drug subsequently became the world’s best-selling diabetes treatment with Actos® with sales peaking between March 2010 and March 2011 at $4.5 billion, or 27 percent of Takeda revenue, according to data compiled by Bloomberg News. In June 2011, the FDA issued a Drug Safety Alert warning that the use of Actos® for more than one year may be associated with an increased risk of bladder cancer.

“We are vigorously pursuing claims on behalf of individuals who allege that they or their loved ones have been diagnosed with bladder cancer as a result of taking Actos for more than one year,” says Kristine Kraft, partner at Schlichter, Bogard & Denton, LLP. Individuals who believe they have suffered such injuries as a result of taking Actos may be entitled to compensation. Partner Kristine Kraft and the attorneys at Schlichter, Bogard & Denton, LLP offer free and confidential case evaluations.

About Schlichter, Bogard & Denton, LLP
Schlichter, Bogard & Denton, LLP is a unique law firm that aggressively represents its clients injured as a result of dangerous pharmaceutical medications and unsafe medical devices. The attorneys at Schlichter, Bogard & Denton, LLP who represent victims harmed by pharmaceutical manufacturers include Roger Denton, Kristine Kraft, Beth Wilkins Flieger, Ashley Brittain Landers, and Tara Rocque. With hard work, creative thinking, and strong trial skills, we have earned an outstanding nationwide reputation by representing thousands of individuals who have suffered serious injuries. If you or a loved one developed bladder cancer after taking Actos® for more than one year, please contact the attorneys at Schlichter, Bogard & Denton, LLP toll-free at 1-800-873-5297 for your confidential and free consultation.

The choice of a lawyer is an important decision and should not be based solely on advertisements. Past results afford no guarantee of future results and every case is different and must be judged on its own merits.


Contact